Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for cash ...

Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) have their first approved therapy, UCB's Kygevvi, ...

In a new episode of the pharmaphorum podcast, recorded at BIO-Europe Spring in Lisbon, Portugal, web editor Nicole Raleigh ...

His teams are trained to read where it will be three passes from now. In Formula 1, race strategy is no longer a gut call at ...

World Bipolar Day, which occurred 30 th March 2026, raises awareness and encourages better understanding of bipolar disorder, ...

Biogen is offering $41 per share for Apellis, with another $4 on offer if C3 inhibitor Syfovre (pegcetacoplan), approved by ...

Centessa Pharma is heading for an acquisition by Eli Lilly, which has offered $6.3 billion for the company, with another $1.5 ...

AstraZeneca's Alexion unit is planning to file a new, long-acting follow-up to its Strensiq therapy for ultra-rare disease ...

Private equity firm Blackstone has said that its latest life sciences fund – BXLS VI – has closed with a total of $6.3 ...

Central to that evolution is the transformation of care delivery. As published in Digital Engineering, digital transformation ...

Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

The data reveal from the phase 1 INLIGHT study of WVE-007 – an oligonucleotide-based gene-silencing drug designed to switch ...